chevron_leftBack
As of 15 June 2026, Zenas BioPharma, Inc. has a market cap of $1.04B USD, ranking #10483 globally and #2139 in the United States.
It ranks #937 in the Healthcare sector, and #173 in the Biotechnology industry.
Key Stats
Market Cap
$1.04BUSD
Enterprise Value
$702.4MUSD
Revenue (TTM)
$10.0MUSD
EBITDA (TTM)
-$211.33MUSD
Net Income (TTM)
-$377.74MUSD
PS Ratio
104.4
PB Ratio
4.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Leon Moulder
open_in_new
Employees
167
Founded
2019
IPO
13 Sep 2024
Website
zenasbio.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.7% | -14% | -3.8% | -18% | -42% | 76% |
News
Loading...
ZBIO Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ZBIO
Zenas BioPharma Inc
ISIN: US98937L1052
Shares Out.:
Shares Outstanding:
63.133M1
Shares Float:
34.677M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
17.52 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
17K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
15K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
3K%
|
-
|
|
NYSE: IQV
|
$26.3B
2K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
2K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
2K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
4K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
4K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
4K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
4K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
3K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
2K%
|
-
|
chevron_leftBack